BCARI expression in prostate cancer: Association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining

Prostate

Volumn 67, Issue 3, 2007, Pages 268-273

  Fromont, Gaëlle ^a,b,e   Vallancien, Guy ^c   Validire, Pierre ^c   Levillain, Pierre ^b   Cussenot, Olivier ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c INSTITUT MUTUALISTE MONTSOURIS   (France)

^d HÔPITAL TENON   (France)

^e University of Poitiers   (France)

Author keywords

Hormone refractory prostate cancer; Human chromosome 16; Loss of heterozygosity; P130CAS; Prostatic neoplasms; Tissue array analysis

Indexed keywords

CD82 ANTIGEN; CRK ASSOCIATED SUBSTRATE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; BCAR1 PROTEIN, HUMAN; KAI1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL MIGRATION; CELL SURVIVAL; CHROMOSOME 16Q; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; GLEASON SCORE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TISSUE MICROARRAY; TUMOR GROWTH; BIOSYNTHESIS; CHROMOSOME 16; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

AGED; CHROMOSOMES, HUMAN, PAIR 16; CRK-ASSOCIATED SUBSTRATE PROTEIN; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KANGAI-1 PROTEIN; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS;

EID: 33846978387     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20516     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Fromont G, Joulin V, Chantrel-Groussard K, Vallancien G, Guillonneau B, Validire P, Latil A, Cussenot O. Allelic losses in localized prostate cancer; association with prognostic factors. J Urol 2003;170:1394-1397.
3. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. Allelic loss of 16q23.2-24.2 is an independant marker of good prognosis in primary breast cancer. Cancer Res 1998;58:2166-2169.
4. Fromont G, Valeri A, Cher M, Pontes JE, Vallancien G, Validire P, Latil A, Cussenot O. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer. Prostate 2005;65:341-346.
5. Brinkman A, van der Flier S, Dorssers L. BCAR1, a human homologue of the adapter protein p130CAS, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000;92:112-120.
6. Bouton AH, Riggins RB, Bruce-Staskal PJ. Functions of the adapter protein CAS: Signal convergence and the determination of cellular responses. Oncogene 2001;20:6448-6458.
7. Takino T, Tamura M, Miyamori H, Araki M, Matsumoto K, Sato H, et al. Tyrosine phosphorilation of the CrkII adaptor protein modulates cell migration. J Cell Science 2003;116:3145-3155.
8. Kim W, Kook S, Kim DJ, Teodorof C, Song WK. The 31-kDa caspase-generated cleavage product of p130CAS functions as a transcriptional repressor of E2A in apoptotic cells. J Biol Chem 2004;279:8333-8342.
9. Doorssers L, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven S, de Jong D, et al. The pronostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 2004;10:6194-6202.
10. Ojaniemi M, Vuori K. Epidermal growth factor modulates tyrosine phosphorilation of p130CAS. J Biol Chem 1997;272:25993-25998.
11. Moro L, Dolce L, Cabodi S, Bergatto E, Boeri Erba E, Smeriglio M, et al. Integrin induced epidermal growth factor receptor activation requires c-Src and p130CAS and leads to phosphorilation of specific EGF receptor tyrosines. J Biol Chem 2002;277:9405-9414.
12. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Sautorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-3444.
13. Ueda T, Ichakawa T, Tamaru J, Mikata A, Akakura K, Akimoto S. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 1996;149:1435-1440.
14. Zhang XA, He B, Zhou B, Liu L. Requirement of the p130CAS-Crk coupling for metastasis supressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem 2003;278:27319-27328.
15. Odintsova E, Sugiura T, Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI1. Curr Biol 2000;10:1009-1012.
16. Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R. Loss of heterozygoty at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1995;1:1385-1389.
17. der Flier S, Chan CM, Brinkman A, Smid M, Johnston SR, Dorssers L, et al. BCAR1/p130CAS expression in intreated and acquired tamoxifen resistant human breast carcinomas. Int J Cancer 2000;89:465-468.
18. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R. Loss of heterozygoty at chromosome 16q in prostate adenocarcinoma: Identification of 3 independant regions. Cancer Res 1997;57:1058-1062.
19. Paige AJW, Taylor K, Steward A, Sgouros JG, Gabra H, Sellar GC, et al. A 7000-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers ans spanning the common fragile site FRA16D. Cancer Res 2000;60:1690-1697.
20. Cabodi S, Moro L, Baj G, Smeriglio M, Di Stefano P, Gippone S, et al. P130CAS interacts with estrogen receptor a and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Science 2004;117:1603-1611.
21. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, lombardi M, De Falco A, et al. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: Steroid antagonist action. Cancer Res 2005;65:10585-10593.
22. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9189.